Nurix Therapeutics (NRIX) Cash & Equivalents (2019 - 2025)
Historic Cash & Equivalents for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $247.0 million.
- Nurix Therapeutics' Cash & Equivalents rose 12451.52% to $247.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $247.0 million, marking a year-over-year increase of 12451.52%. This contributed to the annual value of $247.0 million for FY2025, which is 12451.52% up from last year.
- As of Q4 2025, Nurix Therapeutics' Cash & Equivalents stood at $247.0 million, which was up 12451.52% from $78.4 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Cash & Equivalents registered a high of $247.0 million during Q4 2025, and its lowest value of $33.6 million during Q1 2023.
- Its 5-year average for Cash & Equivalents is $91.3 million, with a median of $78.6 million in 2022.
- In the last 5 years, Nurix Therapeutics' Cash & Equivalents crashed by 7793.23% in 2022 and then skyrocketed by 13412.44% in 2024.
- Nurix Therapeutics' Cash & Equivalents (Quarter) stood at $80.5 million in 2021, then fell by 19.91% to $64.5 million in 2022, then dropped by 15.27% to $54.6 million in 2023, then soared by 101.36% to $110.0 million in 2024, then skyrocketed by 124.52% to $247.0 million in 2025.
- Its Cash & Equivalents stands at $247.0 million for Q4 2025, versus $78.4 million for Q3 2025 and $84.3 million for Q2 2025.